Researcher
Diether Lambrechts
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Lambrechts Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 2003 → 30 Sep 2005 - Department of Cellular and Molecular Medicine (Department)
Member
From1 Oct 1999 → 30 Sep 2003
Projects
21 - 30 of 72
- Single-Cell Omics to Reveal Mechanisms of Response to Immunotherapy in Head and Neck CancerSingle-Cell Omics to Reveal Mechanisms of Response to Immunotherapy in Head and Neck CancerSingle-Cell Omics to Reveal Mechanisms of Response to Immunotherapy in Head and Neck CancerFrom1 Sep 2019 → 1 Sep 2023Funding: Foundations, funds and other with scientific goal
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer.From1 Aug 2019 → 1 Aug 2023Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
- Integrated IMMUnoprofiling of large adaptive CANcer patients cohortsFrom1 Mar 2019 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing, H2020 - European Institute of Innovation and Technology
- Dissecting complex tumor microenvironment dynamics during immune checkpoint inhibition using single-cell profilingFrom1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Unraveling the resistance mechanisms to PI3K/mTOR inhibition and PD-1 blockade in uterine leiomyosarcomaFrom1 Dec 2018 → 30 Nov 2023Funding: Foundations, funds and other with scientific goal
- Genomic Driven Approach to Identify Molecular Biomarkers and Therapeutic Targets for GlioblastomaFrom29 Oct 2018 → 4 Mar 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- SymBioSys: Computationally disentangling cellular heterogeneityFrom1 Oct 2018 → 30 Sep 2022Funding: Fund Recuperation Fiscal Exemption
- Novel applications for immune checkpoint blockers in head and neck cancerFrom1 Sep 2018 → 19 Mar 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Single-cell omics in high throughput and at spatial resolutionFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
Publications
1 - 10 of 609
- Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients.(2024)
Authors: Laudine Janssen, Veerle Boecxstaens, Isabelle Cleynen, Dirk Vanderschueren, Katleen Vandenberghe, Oliver Bechter, Diether Lambrechts, Maria Garmyn
Pages: 125 - 133 - A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial(2024)
Authors: Tine Ottenbourgs, Toon Van Gorp, Thaïs Baert, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
- CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.(2024)
Authors: Amelie Franken, Michel Bila, Aurelie Mechels, Jeroen Van Dessel, Bram Boeckx, Sigrid Hatse, Esther Hauben, Vincent Vander Poorten, Katy Vandereyken, Sabine Tejpar, et al.
Pages: 541 - 558.e7 - Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease.(2024)
Authors: Diether Lambrechts
Pages: 19 - Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.(2024)
Authors: Diether Lambrechts, Jieyi Xiong
Pages: 105003 - Lower respiratory tract single-cell RNA sequencing and neutrophil extracellular trap profiling of COVID-19-associated pulmonary aspergillosis: a single centre, retrospective, observational study.(2024)
Authors: Simon Feys, Sam Vanmassenhove, Bram Boeckx, Seppe Cambier, Yves Debaveye, Greet Hermans, Katrien Lagrou, Johan Neyts, Marijke Peetermans, Joana Duarte Da Rocha Pereira, et al.
Pages: e247 - e260 - Comparison of the single-cell and single-nucleus hepatic myeloid landscape within decompensated cirrhosis patients(2024)
Authors: Lukas Van Melkebeke, Jef Verbeek, Bram Boeckx, Lena Smets, Olivier Govaere, Diether Lambrechts, Schalk Van der Merwe
- A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma(2024)
Authors: Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Katy Vandereyken, Thierry Voet, Wim Annaert, Diether Lambrechts, Veerle Boecxstaens, Joost van den Oord, Francesca Bosisio, et al.
- Heterozygous mutations in the C-terminal domain of COPA underlie a complex autoinflammatory syndrome.(2024)
Authors: Selket Delafontaine, Daisy Rymen, Katrien Jansen, Djalila Mekahli, Rik Schrijvers, Xavier Bossuyt, Bram Boeckx, Lisa Ehlers, Sebastian Munck, Diether Lambrechts, et al.
Pages: e163604 - Integrated analysis of transcriptomic and proteomic alterations in mouse models of ALS/FTD identify early metabolic adaptions with similarities to mitochondrial dysfunction disorders(2024)
Authors: Ingrid Arijs, Diether Lambrechts
Pages: 135 - 149
Patents
1 - 10 of 10
- Predicting chronic allograft injury through age-related dna methylation (Inventor)
- Disease detection in liquid biopsies (Inventor)
- Retrotransposon biomarkers (Inventor)
- Detection of ovarian cancer in liquid biopsies (Inventor)
- Markers for determining tumor hypoxia (Inventor)
- Disease detection in liquid biopsies (Inventor)
- Predicting chronic allograft injury through age-related dna methylation (Inventor)
- Predicting age using dna methylation signatures (Inventor)
- Retrotransposon biomarkers (Inventor)
- Predicting chronic allograft injury through ischemia-induced dna methylation (Inventor)